These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7650686)

  • 1. Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist.
    Duggan ME; Naylor-Olsen AM; Perkins JJ; Anderson PS; Chang CT; Cook JJ; Gould RJ; Ihle NC; Hartman GD; Lynch JJ
    J Med Chem; 1995 Aug; 38(17):3332-41. PubMed ID: 7650686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of orally active, non-peptide fibrinogen receptor antagonists. An evolutionary process from the RGD sequence to novel anti-platelet aggregation agents.
    Bovy PR; Tjoeng FS; Rico JG; Rogers TE; Lindmark RJ; Zablocki JA; Garland RB; McMackins DE; Dayringer H; Tóth MV
    Bioorg Med Chem; 1994 Sep; 2(9):881-95. PubMed ID: 7712124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
    J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro.
    Samanen J; Ali F; Romoff T; Calvo R; Sorenson E; Vasko J; Storer B; Berry D; Bennett D; Strohsacker M
    J Med Chem; 1991 Oct; 34(10):3114-25. PubMed ID: 1920361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists.
    Zablocki JA; Rico JG; Garland RB; Rogers TE; Williams K; Schretzman LA; Rao SA; Bovy PR; Tjoeng FS; Lindmark RJ
    J Med Chem; 1995 Jun; 38(13):2378-94. PubMed ID: 7608903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
    Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist.
    Bondinell WE; Keenan RM; Miller WH; Ali FE; Allen AC; de Brosse CW; Eggleston DS; Erhard KF; Haltiwanger RC; Huffman WF
    Bioorg Med Chem; 1994 Sep; 2(9):897-908. PubMed ID: 7712125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.
    Askew BC; Bednar RA; Bednar B; Claremon DA; Cook JJ; McIntyre CJ; Hunt CA; Gould RJ; Lynch RJ; Lynch JJ; Gaul SL; Stranieri MT; Sitko GR; Holahan MA; Glass JD; Hamill T; Gorham LM; Prueksaritanont T; Baldwin JJ; Hartman GD
    J Med Chem; 1997 Jun; 40(12):1779-88. PubMed ID: 9191954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of a new class of orally active fibrinogen receptor antagonists.
    Klein SI; Molino BF; Czekaj M; Gardner CJ; Chu V; Brown K; Sabatino RD; Bostwick JS; Kasiewski C; Bentley R; Windisch V; Perrone M; Dunwiddie CT; Leadley RJ
    J Med Chem; 1998 Jul; 41(14):2492-502. PubMed ID: 9651154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.
    Egbertson MS; Chang CT; Duggan ME; Gould RJ; Halczenko W; Hartman GD; Laswell WL; Lynch JJ; Lynch RJ; Manno PD
    J Med Chem; 1994 Aug; 37(16):2537-51. PubMed ID: 8057299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orally active non-peptide fibrinogen receptor (GpIIb/IIIa) antagonists: identification of 4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid as a long-acting, broad-spectrum antithrombotic agent.
    Eldred CD; Evans B; Hindley S; Judkins BD; Kelly HA; Kitchin J; Lumley P; Porter B; Ross BC; Smith KJ
    J Med Chem; 1994 Nov; 37(23):3882-5. PubMed ID: 7966149
    [No Abstract]   [Full Text] [Related]  

  • 12. Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217.
    Cook JJ; Holahan MA; Lyle EA; Ramjit DR; Sitko GR; Stranieri MT; Stupienski RF; Wallace AA; Hand EL; Gehret JR; Kothstein T; Drag MD; McCormick GY; Perkins JJ; Ihle NC; Duggan ME; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1996 Jul; 278(1):62-73. PubMed ID: 8764336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
    Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
    J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SC-54684A: an orally active inhibitor of platelet aggregation.
    Nicholson NS; Panzer-Knodle SG; Salyers AK; Taite BB; Szalony JA; Haas NF; King LW; Zablocki JA; Keller BT; Broschat K
    Circulation; 1995 Jan; 91(2):403-10. PubMed ID: 7805244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight, non-peptide fibrinogen receptor antagonists.
    Alig L; Edenhofer A; Hadváry P; Hürzeler M; Knopp D; Müller M; Steiner B; Trzeciak A; Weller T
    J Med Chem; 1992 Nov; 35(23):4393-407. PubMed ID: 1447740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
    Cook NS; Bruttger O; Pally C; Hagenbach A
    Thromb Haemost; 1993 Nov; 70(5):838-47. PubMed ID: 8128443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749).
    Nicholson NS; Panzer-Knodle SG; Salyers AK; Taite BB; King LW; Miyano M; Gorczynski RJ; Williams MH; Zupec ME; Tjoeng FS
    J Pharmacol Exp Ther; 1991 Mar; 256(3):876-82. PubMed ID: 2005585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Halysin, an antiplatelet Arg-Gly-Asp-containing snake venom peptide, as fibrinogen receptor antagonist.
    Huang TF; Liu CZ; Ouyang CH; Teng CM
    Biochem Pharmacol; 1991 Aug; 42(6):1209-19. PubMed ID: 1888330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SR 121787, a new orally active fibrinogen receptor antagonist.
    Savi P; Badorc A; Lalé A; Bordes MF; Bornia J; Labouret C; Bernat A; de Cointet P; Hoffmann P; Maffrand JP; Herbert JM
    Thromb Haemost; 1998 Sep; 80(3):469-76. PubMed ID: 9759629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa.
    Bednar B; Cook JJ; Holahan MA; Cunningham ME; Jumes PA; Bednar RA; Hartman GD; Gould RJ
    Blood; 1999 Jul; 94(2):587-99. PubMed ID: 10397726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.